The Technical Analyst
ADMA Biologics Inc [ADMA]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
ADMA Biologics Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
-1.22% $6.46
America/New_York / 24 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 1 497.25 mill |
| EPS: | -0.130 |
| P/E: | -49.69 |
| Earnings Date: | May 08, 2024 |
| SharesOutstanding: | 231.77 mill |
| Avg Daily Volume: | 2.53 mill |
| RATING 2024-04-24 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Sell | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Strong Buy | |
| P/E: | Strong Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -49.69 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -8.45x |
| Company: PE -49.69 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 6.24 - 6.68 ( +/- 3.42%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-01 | Kestenberg-messina Kaitlin M. | Buy | 192 320 | Common Stock |
| 2024-04-01 | Kestenberg-messina Kaitlin M. | Buy | 300 328 | Stock Option (right to buy) |
| 2024-03-31 | Kestenberg-messina Kaitlin M. | Sell | 2 085 | Common Stock |
| 2024-03-31 | Grossman Adam S | Sell | 21 752 | Common Stock |
| 2024-04-01 | Kestenberg-messina Kaitlin M. | Sell | 0 | Common Stock |
| INSIDER POWER |
|---|
| -15.53 |
| Last 100 transactions |
| Buy: 7 559 578 | Sell: 9 852 560 |
Forecast:
16:00 - $6.46
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $6.46
Forecast 2: 16:00 - $6.46
Forecast 3: 16:00 - $6.46
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $6.46 (-1.22% ) |
| Volume | 1.663 mill |
| Avg. Vol. | 2.53 mill |
| % of Avg. Vol | 65.76 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For ADMA
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $5.14 | N/A | Active |
|---|
ADMA
ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. The company also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.
Last 10 Buy Signals
Latest Press Releases
2024-03-11 07:00:00 - Press Release
Adma Biologics Announces Fda Approvals Of Extended Room Temperature Storage Conditions For Asceniv™ & Bivigam®
Fda approval provides for room temperature (25°c) storage conditions for up to 4 weeks at any point during the 36-month approved shelf life
2024-03-05 07:00:00 - Press Release
Adma Biologics To Participate In The Raymond James Institutional Investor Conference
Ramsey, n.j. and boca raton, fla., march 05, 2024 (globe newswire) -- adma biologics, inc. (nasdaq: adma) (“adma” or the “company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty biologics, today announced adam grossman, president and chief executive officer, will participate in a fireside chat at the raymond james institutional investor conference on march 6, 2024, at 11:35 a.m. et.
2024-02-28 16:10:00 - Press Release
Adma Biologics Announces Cfo Transition
Ramsey, n.j. and boca raton, fla.
2024-02-28 16:05:00 - Press Release
Adma Biologics Announces Fourth Quarter And Full Year 2023 Financial Results And Provides Business Update
4q 2023 total revenue of $73.9 million; fy 2023 total revenue of $258.2 million 4q 2023 adjusted ebitda ( 1 ) of $18.6 million; fy 2023 adjusted ebitda of $40.3 million 4q 2023 adjusted net income ( 2 ) of $8.5 million; fy 2023 adjusted net income of $0.7 million fy 2024 and 2025 total revenue guidance increased to more than $330 million and $380 million, respectively fy 2024 net income guidance increased to more than $65 million and adjusted ebitda guidance increased to more than $90 million fy 2025 net income guidance increased to more than $115 million and adjusted ebitda guidance increased to more than $140 million innovative growth opportunities targeting manufacturing and new pipeline hyperimmune globulin to advance during 2024 conference call scheduled for today at 4:30 p...
2024-02-21 16:05:00 - Press Release
Adma Biologics To Report Fourth Quarter And Full Year 2023 Financial Results On February 28, 2024
Ramsey, n.j. and boca raton, fla.
Latest News
2024-04-24 09:51:15 - Zacks Investment Research
Recent Price Trend in Adma Biologics (ADMA) is Your Friend, Here's Why
Adma Biologics (ADMA) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
2024-04-19 18:51:27 - Zacks Investment Research
Adma Biologics (ADMA) Ascends While Market Falls: Some Facts to Note
In the most recent trading session, Adma Biologics (ADMA) closed at $6.27, indicating a +1.13% shift from the previous trading day.
2024-04-17 18:56:13 - Zacks Investment Research
Adma Biologics (ADMA) Registers a Bigger Fall Than the Market: Important Facts to Note
In the most recent trading session, Adma Biologics (ADMA) closed at $6.04, indicating a -1.95% shift from the previous trading day.
2024-04-15 07:01:05 - Zacks Investment Research
Buy These 4 Low-Beta Stocks to Counter Market Volatility
It is imperative to build a portfolio of low-beta stocks to sail through a volatile market. Trip.com (TCOM), ADMA Biologics (ADMA), Lantheus (LNTH) and Skyward (SKWD) are well-poised to gain.
2024-04-10 18:51:11 - Zacks Investment Research
Adma Biologics (ADMA) Suffers a Larger Drop Than the General Market: Key Insights
Adma Biologics (ADMA) closed at $6.04 in the latest trading session, marking a -1.15% move from the prior day.
2024-04-10 07:51:05 - Zacks Investment Research
5 Stocks With Recent Price Strength to Maximize Your Gain
Investors target stocks that are witnessing a bullish run. Some of the stocks seeing price strength are QFIN, WLDN, HEES, CMPR, AIT.
2024-04-09 12:11:07 - Zacks Investment Research
Is it a Good Idea to Invest in ADMA Biologics (ADMA) Stock Now?
Here, we discuss some reasons why investing in ADMA Biologics (ADMA) stock may turn out to be a prudent move now.
2024-04-05 09:51:17 - Zacks Investment Research
Adma Biologics (ADMA) is on the Move, Here's Why the Trend Could be Sustainable
If you are looking for stocks that are well positioned to maintain their recent uptrend, Adma Biologics (ADMA) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
2024-04-01 18:56:16 - Zacks Investment Research
Adma Biologics (ADMA) Suffers a Larger Drop Than the General Market: Key Insights
In the most recent trading session, Adma Biologics (ADMA) closed at $6.54, indicating a -0.91% shift from the previous trading day.
2024-03-22 18:56:26 - Zacks Investment Research
Why the Market Dipped But Adma Biologics (ADMA) Gained Today
In the closing of the recent trading day, Adma Biologics (ADMA) stood at $6.29, denoting a +1.62% change from the preceding trading day.